Large-cap Health Care company Gilead Sciences has logged a 0.5% change today on a trading volume of 1,099,969. The average volume for the stock is 9,358,004.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. Based in Foster City, United States the company has 17,600 full time employees and a market cap of $137,603,530,752. Gilead Sciences currently offers its equity investors a dividend that yields 2.8% per year.
The company is now trading -4.54% away from its average analyst target price of $115.88 per share. The 26 analysts following the stock have set target prices ranging from $92.0 to $140.0, and on average give Gilead Sciences a rating of buy.
Over the last 52 weeks, GILD stock has risen 71.1%, which amounts to a 59.7% difference compared to the S&P 500. The stock's 52 week high is $119.96 whereas its 52 week low is $62.69 per share. With its net margins declining an average -35.9% over the last 6 years, Gilead Sciences may not have a strong enough profitability trend to support its stock price.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | 28,754,000 | 480,000 | 2 | -90.48 |
| 2023 | 27,116,000 | 5,665,000 | 21 | 23.53 |
| 2022 | 27,281,000 | 4,592,000 | 17 | -26.09 |
| 2021 | 27,305,000 | 6,225,000 | 23 | inf |
| 2020 | 24,689,000 | 123,000 | 0 | -100.0 |
| 2019 | 22,449,000 | 5,386,000 | 24 |
